-
1.发明申请MARKERS AND METHODS FOR ASSESSING AND TREATING SEVERE OR PERSISTANT ASTHMA AND TNF RELATED DISORDERS 审中-公开评估和治疗严重哮喘和TNF相关疾病的标记和方法公开(公告)号：US20100331209A1
公开(公告)日：2010-12-30
申请号：US12867910
申请日：2009-03-19
申请人： Chris Huang , Rosemary Watt , Elliot Barnathan , Kim Hung Lo
发明人： Chris Huang , Rosemary Watt , Elliot Barnathan , Kim Hung Lo
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： A method for assessment of the suitability of and/or effectiveness of a target therapy for a TNF-mediated-related disorder, such as severe or persistent asthma, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes corresponding to contacting the sample with a panel of nucleic acid segments consisting of at least a portion of at least one member from the group consisting of the nucleotide sequences corresponding to at least one of TNFRSF1A SNP rs4149581 (SEQ ID NO:1), TNFRSF1 B SNP rs3766730 (SEQ ID NO:2) or TNFRSFI B SNP rs590977 (SEQ ID NO:3) SNPs which results in a determination that one or more of said SNPs in a sample are in linkage disequilibrium (LD). The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies.
摘要翻译： 用于评估靶标治疗对TNF介导的相关疾病（例如严重或持续性哮喘）在受试者中的适用性和/或有效性的方法评估一种或多种 更多的基因对应于将样品与由至少一部分至少一个成员组成的组中的至少一部分组成的组接触，所述核苷酸序列对应于TNFRSF1A SNP rs4149581（SEQ ID NO：1）， TNFRSF1B SNP rs3766730（SEQ ID NO：2）或TNFRSFI B SNP rs590977（SEQ ID NO：3）SNP，其导致样品中的一种或多种所述SNP处于连锁不平衡（LD）的SNP。 该方法能够在开始患者之前或之后鉴定目标疗法在这些疗法上的有效性。
搜索结果
1 条记录 (耗时 0.017 秒)
